Lumonus, an AI-native oncology workflow platform company, closed a A$25 million Series B led by Aviron Investment Management with continued participation from Oncology Ventures. The funding will expand U.S. go‑to‑market and clinical success teams and advance its products (AI Physician and AI Dosimetry). Lumonus reports its platform has supported clinicians in consulting/prescribing over 280,000 cancer treatments and automated creation of 75,000+ treatment plans across the U.S., Australia, and Europe.
Related articles
Press ReleaseSeptember 16, 2026
ASSA ABLOY
ASSA ABLOY acquires PACLOCK in the US
September 16, 2026
Press ReleaseSeptember 16, 2026
MySize
MySize Announces $2.5 Million Private Placement Priced At-the-Market Under Nasdaq Rules
September 16, 2026
Press ReleaseSeptember 16, 2026
Xpansiv
Xpansiv to Acquire Formbay, Australia's AI-Enabled Renewable Energy Certificate and Compliance Technology Platform
September 16, 2026
← Back to all articles
Generated by Olivia 6